4-HO-MPMI

4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C14H17N2O
Molar mass 229.297 g/mol
3D model (JSmol)
 NY (what is this?)  (verify)

4-HO-MPMI (also known as 4-Hydroxy-N-methyl-(α,N-trimethylene)-tryptamine or lucigenol) is a tryptamine derivative that is a psychedelic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active.[1]

The binding affinity for 5-HT2A receptor is 13 ± 2 nM (Ki [125I]DOI). It is reported at doses starting at 0.5 mg and 1.0-1.5 mg seem to be psychedelic doses. The duration it is reported between six and eight hours. The effects, still not too documented, are OEV/CEV, sedation and anxiety.[2]

See also

References

  1. Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE (1999). "Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain". Journal of Medicinal Chemistry. 42 (20): 4257–4263. doi:10.1021/jm990325u. PMID 10514296.
  2. http://www.hipforums.com/newforums/showthread.php?t=315326
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.